sb 202190 has been researched along with Acute Confusional Senile Dementia in 2 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Semwal, BC | 1 |
| Garabadu, D | 1 |
| Chong, YH | 1 |
| Sung, JH | 1 |
| Shin, SA | 1 |
| Chung, JH | 1 |
| Suh, YH | 1 |
2 other studies available for sb 202190 and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
5-N-ethyl Carboxamidoadenosine Stimulates Adenosine-2b Receptor-Mediated Mitogen-Activated Protein Kinase Pathway to Improve Brain Mitochondrial Function in Amyloid Beta-Induced Cognitive Deficit Mice.
Topics: Adenosine A2 Receptor Agonists; Adenosine-5'-(N-ethylcarboxamide); Alzheimer Disease; Amyloid beta-P | 2020 |
Effects of the beta-amyloid and carboxyl-terminal fragment of Alzheimer's amyloid precursor protein on the production of the tumor necrosis factor-alpha and matrix metalloproteinase-9 by human monocytic THP-1.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Antibodies; Cell Line; Dru | 2001 |